Dr. Wierda Discusses Trials of Novel Combinations in CLL

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses trials of novel combinations on chronic lymphocytic leukemia (CLL).

The combination of ibrutinib (Imbruvica), cyclophosphamide, fludarabine, and obinutuzumab (Gazyva) is currently being tested at MD Anderson in younger patients with a mutated immunoglobulin heavy chain variable gene.

Additionally, a study of ibrutinib plus venetoclax (Venclexta) is currently ongoing, and data on that combination will be presented at this year’s ASH Annual Meeting.